November 2010

 

OPHTHALMOLOGY NEWS

 

FDA Approves Cataract Postoperative Inflammation Eye Drop


   

The Food & Drug Administration has given the green light to Bromday, a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in cataract patients. The drop was developed by ISTA Pharmaceuticals, Inc., Irvine, Calif. Currently, the drop is approved for dosing beginning one day prior to surgery, the day of surgery, and continuing for the first 14 days after surgery.

"We believe the convenience of a once-daily eye drop will help with treatment compliance and benefit patients recovering from cataract surgery," said Dr. Vicente Anido Jr., Ph.D., president and chief executive officer of ISTA, in a press release. ISTA will begin detailing Bromday to ophthalmologists by mid-November.

Reported by: EyeWorld News Services

FDA Approves Cataract Postoperative Inflammation Eye Drop FDA Approves Cataract Postoperative Inflammation Eye Drop
Ophthalmology News - EyeWorld Magazine
283 110
283 110
,
2016-07-08T15:40:10Z
True, 11